DelMar Pharmaceuticals Inc (NASDAQ:DMPI) has been assigned an average broker rating score of 1.50 (Buy) from the four analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation and three have given a strong buy recommendation to the company.
Brokerages have set a one year consensus price target of $9.95 for the company and are anticipating that the company will post ($0.15) earnings per share for the current quarter, according to Zacks. Zacks has also given DelMar Pharmaceuticals an industry rank of 171 out of 265 based on the ratings given to its competitors.
Separately, HC Wainwright set a $12.00 price objective on DelMar Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, January 4th.
DelMar Pharmaceuticals (NASDAQ:DMPI) last issued its quarterly earnings data on Monday, November 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). equities research analysts anticipate that DelMar Pharmaceuticals will post -0.54 earnings per share for the current fiscal year.
In other news, CEO Saiid Zarrabian acquired 60,900 shares of DelMar Pharmaceuticals stock in a transaction dated Tuesday, November 14th. The stock was bought at an average price of $0.82 per share, for a total transaction of $49,938.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Hedge funds have recently modified their holdings of the stock. Franklin Resources Inc. bought a new stake in shares of DelMar Pharmaceuticals in the second quarter valued at approximately $2,477,000. Sabby Management LLC bought a new stake in shares of DelMar Pharmaceuticals in the second quarter valued at approximately $1,484,000. Finally, Susquehanna International Group LLP bought a new stake in shares of DelMar Pharmaceuticals in the third quarter valued at approximately $306,000. Institutional investors and hedge funds own 16.91% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2018/01/19/delmar-pharmaceuticals-inc-dmpi-receives-average-rating-of-buy-from-brokerages.html.
DelMar Pharmaceuticals Company Profile
DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.